ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 6 for:    "Piebaldism"

A Multicenter Trial of Non-cultured Epidermal Cellular Grafting Versus Hyaluronic Acid for Repigmenting Stable Leukoderma (Vitiligo and Piebaldism)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02156427
Recruitment Status : Unknown
Verified July 2015 by Laboratoires Genévrier.
Recruitment status was:  Recruiting
First Posted : June 5, 2014
Last Update Posted : July 9, 2015
Sponsor:
Information provided by (Responsible Party):
Laboratoires Genévrier

Brief Summary:

The purpose of this study is to assess the efficacy of autologous epidermal cells suspension grafting using a newly developed device named VITICELL® compared to placebo.

The secondary objective is to evaluate safety of VITICELL® and global satisfaction of patient and investigator.


Condition or disease Intervention/treatment Phase
Vitiligo Piebaldism Device: VITICELL Device: PLACEBO Phase 3

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 60 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : May 2014
Estimated Primary Completion Date : September 2016


Arm Intervention/treatment
Experimental: VITICELL
In this arm, lesions will be treated by autologous epidermal cells suspension (containing hyaluronic acid) obtained after VITICELL kit's use, a class III medical device.
Device: VITICELL
Sham Comparator: PLACEBO
In this arm, lesions will be treated by a suspension of hyaluronic acid without epidermal cells.
Device: PLACEBO



Primary Outcome Measures :
  1. Successful repigmentation: more than or equal to 50% repigmentation of the treated area [ Time Frame: up to month 12 ]

Secondary Outcome Measures :
  1. Repigmentation rate ≥ 50% of the treated area [ Time Frame: month 12 ]

Other Outcome Measures:
  1. Number of adverse events in each group [ Time Frame: Day 0/Day 6-7/Month 3/6/9/12 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women aged over 18 years old with a diagnosis of non-scaring leukoderma that has been stable over the last 2 years (non-segmental, segmental vitiligo and piebaldism)
  • For non-segmental vitiligo: symmetrical vitiligo lesions, or parts of a lesion. A part of at least 1 cm2 (1 x 1 cm), but preferable 4 cm2 (2x2 cm) and preferably in the center of each lesions (left/right) should be treated.

The minimum distance between the normal pigmented skin and the test area should preferably be at least 0.5 cm.

  • For segmental vitiligo lesion and piebaldism: all lesions possible if two parts of at least 1 cm2 (1 x 1 cm), but preferably 4 cm2 (2 x 2 cm) in the lesion can be treated. The minimum distance between the 2 areas should be 2 cm and between test areas and to the normal pigmented skin preferably at least 0.5 cm.
  • Medical treatments of vitiligo failed (in case of vitiligo: at least cream treatment for 6 months).
  • Absence of infected lesion
  • Negative serology (HIV-hepatitis B and C- Syphilis)
  • Without treatment one month for cream and 3 months for phototherapy

Exclusion Criteria:

  • Hypersensibility to local anaesthetics or one of the components of the device (trypsin, hyaluronic acid)
  • Indication against biopsies
  • Patient with a history of melanoma
  • Positive serology (ongoing serious systemic disease, herpes, HIV, hepatitis B and C-Syphilis)
  • Positive pregnancy test
  • History of keloidal scars and presence of Koebner's phenomenon (type 1 and type 2b)
  • Infected lesion
  • Test areas not on fingers and toes vitiligo areas in case of non-segmental vitiligo
  • Test areas not on facial non segmental vitiligo
  • Pregnant women, or lactating
  • Age <18years
  • Major deprived of their freedom by administrative or legal decision, or being the subject of a legal protection measure, or out of state to express their consent

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02156427


Contacts
Contact: Anissa Taverne, Dr. + 33 492914134 ataverne@laboratoires-genevrier.com

Locations
Belgium
Department of Dermatology - Ghent University Hospital Recruiting
Ghent, Belgium
Contact: Nanja van Geel, Prof. Dr.    + 32-93322298    Nanja.vangeel@UGent.be   
Principal Investigator: Nanja Van Geel, Prof. Dr.         
France
University Hospital Center of Bordeaux Recruiting
Bordeaux, France
Contact: Alain Taieb, Pr    +33 556794975    alain.taieb@chu-bordeaux.fr   
Principal Investigator: Alain Taieb, Pr         
Sub-Investigator: Antoine Bertolotti, Dr         
Sub-Investigator: Julien Senechal, Dr         
CHU Le Mans Recruiting
Le Mans, France
Contact: Hervé Maillard, Dr    +33 243434358      
Dr Michel PASCAL Recruiting
Paris, France
Contact: Michel Pascal, Dr    +33 143679259    pascalmichel1@mac.com   
Italy
San Gallicano Dermatological Institute Recruiting
Roma, Italy
Contact: Giovanni Leone, Dr.    + 39-0652665982    gleone@ifo.it   
Principal Investigator: Giovanni Leone, Dr.         
Sponsors and Collaborators
Laboratoires Genévrier

Responsible Party: Laboratoires Genévrier
ClinicalTrials.gov Identifier: NCT02156427     History of Changes
Other Study ID Numbers: 13INT/VIT01
First Posted: June 5, 2014    Key Record Dates
Last Update Posted: July 9, 2015
Last Verified: July 2015

Additional relevant MeSH terms:
Piebaldism
Vitiligo
Hypopigmentation
Pigmentation Disorders
Skin Diseases
Albinism
Eye Diseases, Hereditary
Genetic Diseases, Inborn
Amino Acid Metabolism, Inborn Errors
Metabolism, Inborn Errors
Skin Diseases, Genetic
Metabolic Diseases
Hyaluronic Acid
Adjuvants, Immunologic
Immunologic Factors
Physiological Effects of Drugs
Viscosupplements
Protective Agents